Table 1.
Recent post OLT HBV prophylaxis with NUC and/or HBIG
| No. of patients | HBV DNA positivity at OLT | HBV DNA recurrence | Follow up (months) | Reference no. | Year published | |
|---|---|---|---|---|---|---|
| (a) Lamivudine + HBIG | ||||||
| HBIG i.v. 10 000 IU/month | 14 | 7% (1/14) | 0 | 13 | 5 | 1998 |
| HBIG i.m. 4300–6800 IU/month | 7 | 0% (0/7) | 0 | 17 (13–21) | 14 | 1999 |
| HBIG i.v. 5000 IU/month | 26 | 27% (7/26) | 4% | 30 ± 8 | 15 | 2001 |
| HBIG i.m. 1480 IU/month | 10 | 20% (2/10) | 10% | 15 (10–21) | 17 | 1999 |
| HBIG i.m. 400–800 IU/month | 141 | 76% (72/94) | 4% | 62 (11–126) | 18 | 2007 |
| (b) Lamivudine + HBIG (on demand) | ||||||
| HBIG i.v. to maintain HBsAb >200 IU/L | 21 | 38% (8/21) | 9.5% | 21 (2.4–49.1) | 19 | 2001 |
| HBIG to maintain HBsAb >100 IU/L | 254 (64 FH) | 21% (53/254) >5 log copies/mL | 8.2% (DNA <5 or ≥5 log copies/mL: 3.8% and 20.8%, respectively) | 60 | 20 | 2010 |
| HBIG to maintain HBsAb >70 IU/L | 11 | 0% (0/11) | 0 | 16 (9–22) | 21 | 2004 |
| HBIG IV to maintain HBsAb >10 IU/L | 18 | 61% (11/18) | 0 | 30 (7–73) | 22 | 2007 |
| Short course (6 months) HBIG | 51 | 45% (23/51) | 9.8% (DNA+, 22%; DNA−, 0%) | DNA+ 28 (1–82), DNA− 70 (5–104) | 23 | 2004 |
| Short course (1 month) HBIG | 14 | 0% (0/14) | 7% | 18 | 24 | 2003 |
| (c) Lamivudine + adefovir + HBIG | ||||||
| HBIG to maintain HBsAb >100 IU/L + ADV 114 days before OLT | 11 | 82% (9/11) | 0 | 29 (16–64) | 25 | 2005 |
| HBIG + LAM 4.4 years and HBIG replaced by ADV | 16 | 19% (3/16) | 0 | 21 (9.4–35.9) | 26 | 2008 |
| LAM + ADV short course (7 days) HBIG i.m. 800 IU/day | 20 | 68% (13/19) | 0 | 57 (27–83) | 27 | 2013 |
| One year HBIG i.m.; 2000 IU/month Lamivudine + adefovir or tenofovir, tenofovir, entecavir |
16 | 4.5% (2/44) | 0 | 24 (6–40) post-HBIG withdrawal | 28 | 2012 |
| (d) Entecavir + HBIG | ||||||
| HBIG i.m. to maintain HBsAb >100 IU/L | 63 | Average 5.49 × 104 copies/mL | 0 | 41 (33–54) | 29 | 2012 |
| HBIG >200 IU/L + ETV | 26 | 46% (12/26) | 0 | 25 (0.2–58.6) | 30 | 2013 |
| HBIG >100 IU/L + ETV | 84 | 44 cases <105 copies/mL | 0 | 57.1 ± 15.9 | 31 | 2014 |
| HBIG; dose not specified | 61 | All cases <172 IU/mL | 0 | 18 | 32 | 2013 |
| One year HBIG i.v.; 10 000 U/month | 29 | 52% (15/29) | 3.4% | 31 | 33 | 2013 |
| (e) Tenofovir + emtricitabine + perioperative HBIG | ||||||
| HBIG >6 months to maintain HBsAb >100 IU/L replaced with TDF/EMT | 21 | 56% (10/18) | 0 | 31 (15–47) | 34 | 2012 |
| HBIG >6 months; various protocols | 17 | 88% (15/17) | 0 | 26 (4–36) | 35 | 2013 |
| (f) HBIG-free with newer NUC | ||||||
| Entecavir | 80 | 74% (59/80) | 1.2% (22.5% for HBsAg seropositivity) | 26 (5–40) | 36 | 2011 |
| Lamivudine + adefovir (no HBIG when HBV DNA <3 log10 IU/mL) | 28 | 35% (10/28) | 0 | 22 (10–58) | 27 | 2013 |
| Entecavir, lamivudine + adefovir, tenofovir, entecavir + tenofovir (no HBIG when HBV DNA <3.3 log10 IU/mL) | 75 (ENT 42, LAM + ADV 19, TDF 12, ENT + TDF 2) | 31% (18/57) | 8% (5/6 patients withdrawn from NUC therapy) | 21 (1–83) | 37 | 2013 |
ADV, adefovir dipivoxil; EMT, emtricitabine; ENT, entecavir; ETV, entecavir; FH, fulminant hepatic failure; HBIG, hepatitis B immunoglobulin; HBsAb; HBV DNA, hepatitis B virus DNA; HBV, hepatitis B virus; hepatitis B surface antibody; IU, international units; LAM, lamivudine; NUC, nucleoside/nucleotide analog; OLT, orthotopic liver transplantation; TDF, tenofovir.